Innate Pharma S.A. (IPHYF) Financials

IPHYF Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 71.8 million 96.7 million
Dec. 31, 2025 73.6 million 99.1 million
June 30, 2025 109.5 million 103.5 million
March 31, 2025 120.1 million 110.6 million

IPHYF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -24.8 million ?
Dec. 31, 2025 -25.4 million ?
June 30, 2025 -36.8 million 1.8 million
March 31, 2025 -10.9 million 2.4 million

IPHYF Net Income

No data available :(

IPHYF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 39.3 million - -
Dec. 31, 2025 40.3 million 16.2 million 450802
June 30, 2025 70.8 million 21.1 million 724876
March 31, 2025 87.4 million - -

IPHYF Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 104.7 million
Dec. 31, 2025 107.3 million
June 30, 2025 102.5 million
March 31, 2025 87.7 million

IPHYF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 93933 26.5 million 1.6 million -
Dec. 31, 2025 96228 27.1 million 1.4 million -
June 30, 2025 68362 24.2 million 11.5 million 183871
March 31, 2025 116835 24.8 million 2.7 million 177417

IPHYF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 1.3 million -
Dec. 31, 2025 1.3 million -
June 30, 2025 5.7 million 24.2 million
March 31, 2025 298580 -31.5 million

IPHYF

Price: $1.65

52 week price:
1.31
2.25

Earnings Per Share: -0.64 USD

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 154.9 million

Links: